Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Open-Label, Single-Dose, Four-Period, Two-Sequence, Fully Replicated Crossover Bioequivalence Study of Rivaroxaban 2.5 mg Tablets in Healthy Adult Participants Under Fasting and Fed Conditions

NCT07807488 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT07807488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Open-Label, Single-Dose, Four-Period, Two-Sequence, Fully Replicated Crossover Bioequivalence Study of Rivaroxaban 2.5 mg Tablets in Healthy Adult Participants Under Fasting and Fed Conditions
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2022
Completion date
April 25, 2022
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants